UA Home | AHSC | College of Medicine
To Teach To Heal To Discover


Father’s Day Council Tucson Endowed Chair for Type 1 Diabetes

For the past 19 years, Father’s Day Council Tucson (FDC) has supported improving the lives of children with type 1 diabetes.

FDC has made an ambitious commitment by establishing the Father’s Day Council Tucson Endowed Chair for Type 1 Diabetes. They have committed to raise $1 million by their 20th anniversary. Already, FDC has raised more than $800,000.

The endowed chair will support type 1 diabetes training programs for medical students, residents, and fellows. In addition, post-doctoral fellows and graduate student researchers will receive support for their type 1 diabetes studies. And the endowment will enhance existing clinical programs and services at the Steele Center’s Angel Wing for Children with Diabetes.

Clinical Studies—Research Consortia

Type 1 Diabetes TrialNet
TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Europe, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.

We are currently participating in two TrialNet Studies:

  • TN01-Natural History Study of the Development of Type 1 Diabetes.  NCT00097292.  Site PI: Kurt Griffin 
    Enrollment: ongoing: close relatives of people with Type 1 Diabetes, ages 1-45.

The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study  will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. These results will also be used to identify people eligible to enroll in prevention studies, such as the oral insulin study (below).

  • TN07- Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus NCT00419562.  Site PI: Kurt Griffin  
    Enrollment: Starting May 2011. Relatives of people with Type 1 Diabetes, positive anti-insulin antibodies, and normal glucose tolerance test, Ages 3-45

This study is based on findings from the “Diabetes Prevention Trial of Type 1 Diabetes” study. Although the overall results showed that for the entire study population, oral insulin did not delay or prevent Type 1 diabetes, an analysis that was done after the conclusion of the trial suggested a potential beneficial effect in a subgroup of participants. The participants who seemed to benefit from oral insulin had higher levels of insulin autoantibodies, which are directed against insulin itself and were still making insulin in their pancreas.  This Oral Insulin study will test the extent to which this intervention may prevent or delay type 1 diabetes. 

Immune Tolerance Network
The Immune Tolerance Network is an international clinical research consortium founded by the National Institutes of Health, whose mission is to accelerate the clinical development of immune tolerance therapies through a unique development model.

  • T1DAL-Inducing Remission in Type 1 Diabetes With Alefacept.  NCT00965458.  Site PI:  Kurt Griffin.  
    Enrollment: Starting May 2011: Ages 16-35, recently Diagnosed with Type 1 Diabetes. 

    Starting Fall 2011: ages 12-35, recently Diagnosed with Type 1 Diabetes. 
    The purpose of this trial is to test whether an immunomodulating drug approved for psoriasis (alefacept) will slow or halt destruction of the beta cells in the pancreas. If the destruction of the beta cells is stopped the patients might be able to produce insulin on their own longer which could stop or slow the progression of their type 1 diabetes. 


Clinical Studies--Industry-Sponsored

Colesevelam Pediatric Type 2 Diabetes Mellitus Study. (WELKid DM, Daiichi-Sankyo) NCT01258075. Site PI: Chetan Patel.  
Enrollment: ongoing.  Type 2 Diabetes, not using insulin, ages 10-17.

Colesevelam oral suspension will be studied as treatment of type 2 diabetes mellitus to evaluate clinical safety and efficacy in patients aged 10-17 years.

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes. (Amylin Pharmaceuticals, Inc.) NCT00658021. Site PI: Mark Wheeler.  
Enrollment: ongoing. Type 2 Diabetes not taking insulin, ages 10-17.

The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) with exenatide is superior to that of placebo adolescent patients with type 2 diabetes.

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes. (DIAPREVENT, Diamyd Therapeutics AB) NCT00751842. Site PI: Mark Wheeler
Enrollment: completed; follow-up is ongoing.

The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.

Clinical Studies--Investigator-initiated Studies

TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes.  NCT00684658.  PI:  Melissa Faulkner DSN, RN.  Enrollment: closed. Type 1 Diabetes for > 6 months, ages 11-14.

The purpose of the study is to compare the effects of a 5-week internet-based coping skills training program (TeenCope) with a 5-week internet education program (Managing Diabetes) in youth (age 11-14) with type 1 diabetes on intensive insulin therapy.

Personalized Exercise for Adolescents With Diabetes. NCT00686283.  PI: Melissa Faulkner DSN, RN.  Enrollment: closed.

This study aims to determine the likely benefits of a study that would use the novel techniques both of writing an exercise "prescription" and of including the family and/or community in sticking to the exercise prescription by youths with diabetes, who often suffer eventual cardiovascular complications that might be lessened by the exercise.



Comments to our site editor.

UA College of Medicine : Arizona Health Sciences Center : The University of Arizona

Steele Children's Research Center
1501 N. Campbell Avenue, Suite 3301
PO Box 245073
Tucson, Arizona 85724
Phone: (520) 626-2221

All contents ©2013 Arizona Board of Regents. All rights reserved.
The University of Arizona is an EEO/AA - M/W/D/V Employer.